Pamela Schnupf is awarded the 2019 Prix Bettencourt Coup d’élan
Over the past 20 years, the Foundation Bettencourt Schuller has awarded the Prix Coup d’élan to two CNRS and two INSERM researchers to support them in creating their team or new research unit. This year, our newly recruited group leader Pamela Schnupf is one of the recipients of this prestigious French research prize. [...]
Ganna Panasyuk is awarded a 2018 ERC consolidator grant
In 2018, the European Research Council (ERC) awarded Four Starting Grants, one Synergy Grant and two Consolidator Grants to French National Institute for Biomedical Research (Inserm) researchers. We are proud to announce that Ganna PANASYUK has won the prestigious European Research Council (ERC) Consolidator award in 2018 to develop her research program at our Necker-Enfants Malades [...]
Guillaume Canaud reçoit le Grand Prix 2018 Jean-Pierre Lecocq de l'Académie des Sciences
Guillaume Canaud, maître de conférences Universitaire-Praticien Hospitalier, Néphrologue Adulte à l’hôpital Necker-Enfants Malades AP-HP, Université Paris Descartes, INSERM U1151, a récemment obtenu le Grand Prix Jean-Pierre Lecocq de l’Académie [...]
The Institut Necker-Enfants Malades (INEM), created in January 2014, is an international biomedical research center located on the Necker Hospital campus, and supported by the French National Institute of Health and Medical Research (INSERM), the French National Center for Scientific Research (CNRS) and the University Paris Descartes.
Research at INEM is focusing on common diseases caused by the interplay of polygenic inheritance and environmental factors. These diseases primarily affect children and the young, and encompass (auto)immune disorders, haematological diseases, infectious diseases, kidney diseases, cystic fibrosis, endocrinological disorders and metabolic diseases. The INEM teams apply insights obtained through basic and clinical research to develop innovative diagnostic and therapeutic strategies.
For over 40 years, the development of renal transplants and bone marrow transplants, the phenotyping of autoimmune diseases and genetic diseases, allowed most of the major medical advances of today. The major asset of the Institute Necker-Enfants Malades comes from the plurality of skills, the freedom and creativity of its researchers, their desire to diversify their research topics.
Translational activities will be pursued and promoted as much as possible. Indeed, this group of PIs has filed 24 patents, 4 of which are licenced to pharmaceutical companies. 13 R&D contracts have been signed with industry and 3 start-up companies incorporated with one of the above PIs as founder. To further strengthen the link with the socio-economic world, we intend to devote one floor of our research building to hosting private entities, either small companies or teams from bigger pharmaceutical industries wishing to collaborate with groups of the Necker-Enfants Malades Institute.
The close interaction between the research labs and the clinical departments is one of our major strengths creating a highly dynamic environment and promoting translational and “bench to bedside” activities. Our research programs are consistent with this mission and most groups have very tight connections with the clinics, mostly through clinicians with joint appointments in research labs and clinical departments.
Our research in the coming years will focus on:
Understanding the molecular mechanisms of leukemia is to use targeted therapies and avoid chemotherapy whose collateral damage is known
Defeating diabetes, especially the type 1 in children (440,000 in the world), is to address the treatment of autoimmune diseases, more and more frequent in developed countries, as the case for multiple sclerosis or lupus.
Succeed one day to control the immune system, thanks to the long experience and considerable clinical material at the Necker hospital on kidney and bone marrow transplantations, is a priority
Seek to determine the mechanisms responsible for bacterial meningitis, debilitating in a few hours a perfectly healthy child or subject, is essential to develop effective and safe vaccines.
Apply our knowledge of metabolism and growth to promote innovative and personalized therapies in the field of kidney disease, diabetes, cystic fibrosis, muscular dystrophy and various solid tumors.
The Necker-Enfants Malades Institute is administered by one Director assisted by the two department Heads and one General secretary in charge the administration. Each PI or CoPI is responsible for his (her) scientific project and for the use of his (her) allocated space
Thirteen research teams are founding members of the Necker-Enfants Malades Institute, which comprises today 17 research teams. The teams are grouped in two departments: a department of cell biology (Growth and Signalling) and a department of, Immunology, Infectiology and Haematology (I2H).
The Necker-Enfants Malades Institute currently comprises 103 senior scientists, one third of whom are medical doctors, 60 technicians and engineers, 35 postdoctoral fellows and 37 PhD students. Among the 19 teams, 7 have already obtained an award from the European Research Council.
+33 (0)1 72 60 63 90 +33 (0)1 72 60 64 05
Institut Necker Enfants Malades
Faculté de Médecine Necker
160, rue de Vaugirard
75015 Paris Cedex
HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.
Notice: Undefined index: screen_height in /homepages/40/d483507699/htdocs/index.php on line 345